Native MAG-1 antibody almost destroys human breast cancer xenografts.

Breast Cancer Research and Treatment
William G NorthBernard Cole

Abstract

A native form of mouse monoclonal IgG1 antibody called MAG-1, which recognizes an epitope on provasopressin, has been found to shrink and produce extensive necrosis of human breast tumor xenografts in nu/nu mice. We examined the ability of (90)Yttrium-labeled and native MAG-1 to affect the growth in nu/nu mice of cancer xenografts that were estrogen-responsive (from MCF-7 cells) and triple-negative (from MDA-MB231 cells). The growth rates of treated cells were compared to those receiving saline vehicle and those receiving (90)Yttrium-labeled and native forms of the ubiquitous antibody, MOPC21. Short-term treatments (4 doses over 6 days) not only with (90)Yttrium-MAG-1 but also native MAG-1 produced large reductions in size of rapidly growing tumors of both types, while both (90)Yttrium- MOPC21 and native MOPC21 had no effect. Native and (90)Yttrium-MAG-1 effects were similar, and arrested tumors recommenced growing soon after treatments stopped. Increasing native MAG-1 treatment to single dosing for 16 consecutive days shrank tumors of both types with no regrowth apparent over a 20-day post-treatment period of observation. Pathological examination of such tumors revealed they had undergone very extensive (>66%) necrosis.

References

Jun 1, 1968·Proceedings of the National Academy of Sciences of the United States of America·D Schubert
May 5, 2000·Experimental Physiology·W G North
Apr 9, 2005·Endocrine Reviews·Robert W BrueggemeierEdgar S Diaz-Cruz
Nov 11, 2005·Applied Immunohistochemistry & Molecular Morphology : AIMM·William G NorthBrendan P Keegan
Dec 7, 2005·Breast Cancer Research and Treatment·Brendan P KeeganWilliam G North
Jan 13, 2006·British Journal of Pharmacology·V Craig Jordan
Feb 1, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S RodenhuisUNKNOWN Netherlands Working Party on Autologous Transplantation in Solid Tumours
Sep 15, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·U De GiorgiM Marangolo
Jan 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G ValabregaM Aglietta
Oct 19, 2007·The New England Journal of Medicine·Michalis V KaramouzisAthanasios G Papavassiliou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.